HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmidt, D. Articles by Utech, K. Search for Related Content PubMed PubMed Citation Articles by Schmidt, D. Articles by Utech, K.

Progabide for refractory partial epilepsy

A controlled add-on trial

Neurologische Klinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, Munich, West Germany.

Progabide, an experimental GABA-ergic antiepileptic drug, was given in a placebo-controlled double-blind cross-over trial to 19 adult patients with chronic partial epilepsy refractory to previous high-dose antiepileptic drug therapy. A mean daily dose of 32 mg/kg (range, 16 to 63) of progabide did not significantly change the seizure frequency. In patients with a therapeutic response, progabide led to an increase in the plasma concentration of phenytoin and phenobarbital. Comedication with carbamazepine was associated with a poor response to progabide. Side effects were mild except for a several-fold increase of SGOT and SGPT, which required withdrawal of progabide in one patient. Progabide does not seem to be the drug urgently needed for failures of previous high-dose drug therapy.

Address correspondence and reprint requests to Dr. Schmidt, Neurologische Klinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, Marchioninistrasse 15, 8000 München 70, West Germany.

Accepted for publication May 21, 1985.

This article has been cited by other articles:

				R. B. Carter, P. L. Wood, S. Wieland, J. E. Hawkinson, D. Belelli, J. J. Lambert, H. S. White, H. H. Wolf, S. Mirsadeghi, S. H. Tahir, et al. Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3alpha -Hydroxy-3beta -methyl-5alpha -pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the gamma -Aminobutyric AcidA Receptor J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1284 - 1295. [Abstract] [Full Text]

				J. T. Hutton, J. W. Albrecht, G. C. Roman, and M. T. Kopetzky Prolonged Serum Levodopa Levels With Controlled-Release Carbidopa-Levodopa in the Treatment of Parkinson's Disease Arch Neurol, January 1, 1988; 45(1): 55 - 57. [Abstract] [PDF]

				R. Kurlan Dietary Therapy for Motor Fluctuations in Parkinson's Disease Arch Neurol, November 1, 1987; 44(11): 1119 - 1121. [Abstract] [PDF]